OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
July 22, 2021
Catalent Biologics has launched its new cell line expression technology, GPEx Lightning, which aims to shorten drug substance development timelines by up to three months.
June 03, 2021
The emergence of new biotherapeutics is both the driver and result of innovative drug development technologies.
April 06, 2021
The company has introduced Opto Assure, a series of assays that provide yield and product quality data at an earlier stage in cell-line development.
November 05, 2020
Samsung Biologics has adopted Solentim’s cell seeding and cell metric platforms at its new R&D center in San Francisco, CA.
November 04, 2020
Mogrify’s new technology platform, EpiMOGRIFY, can predict cellular switches important for determining cell identity, cell maintenance, directed differentiation, and cell conversion.
August 13, 2020
The company has made several moves in recent weeks to expand manufacturing capacity and cell line services.
June 11, 2020
The candidates will be used by the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
June 10, 2020
Catalent will use its GPEx cell line development technology to create a cell line expressing the recombinant VLP at its Madison, WI facility.
April 30, 2020
Solentim and ATUM will bundle together the Leap-In Transposase platform with the VIPS single cell cloning instrument for cell line development.
April 16, 2020
This milestone achievement will allow the companies to move forward with developing a GMP-compliant manufacturing process for clinical testing.